Filter by Year

Filter by Topic

2015 News Releases

Thursday, 19 November 2015
JERUSALEM--(BUSINESS WIRE)--Nov. 19, 2015-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and University College London (UCL) announced today the start of a unique study, combining state-of-the-art brain imaging with key biomarkers, aimed at building a better understanding of the role of inflammation in neurodegenerative disease and potentially a new approach in its early diagnosis and treatment.

​The Pilot Longitudinal Study in Alzheimer’s Disease of Central Markers of Microglial Activation (PADMMA) study is a two-year study in 20 patients that will assess, using PET imaging, the prevalence and pattern of activation of a specific type of cell, called microglia, in the central nervous system (CNS) in people with certain symptoms of neurodegenerative disease. It is key demonstration of Teva's commitment towards dementia research made following the UK Government’s Dementia Summit, spearheaded by UK Prime Minister David Cameron. The role of inflammation is key in the field of neurodegen Read More »

Wednesday, 15 April 2015
​Fourth annual PatientView survey identifies Teva as a “Corporate Star” in the eyes of patients. Making medicines accessible is key to patient groups.

Patients Speak: Teva is a Corporate Star    According to 165 patient groups with an interest in neurological conditions, Teva is a “Corporate Star”. This is the result of a 2014 global survey carried out by PatientView which assessed corporate reputation of the top 18 pharmaceutical companies worldwide.   In Second Place Overall   Teva was ranked in second place overall by neurological patient groups. The Company received high scores for our record on patient safety and transparency. Moreover, patients noted our dedication to the continued development of CNS-focused treatments and our Read More »